{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T20:58:20Z","timestamp":1793739500461,"version":"4.6.1"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Interferon-gamma release assays (IGRAs) are approved for children \u22652 years old to aid in diagnosis of <jats:italic toggle=\"yes\">Mycobacterium tuberculosis<\/jats:italic> (TB) infection and disease. Tuberculin skin tests (TSTs) continue to be the recommended method for diagnosis of TB infection in children &lt;2 years, in part due to limited data and concern for high rates of uninterpretable results.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We performed a retrospective cohort study of IGRA use in patients &lt;2 years old in 2 large Boston healthcare systems. The primary outcome was the proportion of valid versus invalid\/indeterminate IGRA results. Secondary outcomes included concordance of IGRAs with paired TSTs and trends in IGRA usage over time.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 321 IGRA results were analyzed; 308 tests (96%) were valid and 13 (4%) were invalid\/indeterminate. Thirty-seven IGRAs were obtained in immunocompromised patients; the proportion of invalid\/indeterminate results was significantly higher among immunocompromised (27%) compared with immunocompetent (1%) patients (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001). Paired IGRAs and TSTs had a concordance rate of 64%, with most discordant results in bacille Calmette-Gu\u00e9rin\u2013vaccinated patients. The proportion of total TB tests that were IGRAs increased over the study period (Pearson correlation coefficient 0.85, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The high proportion of valid IGRA test results in patients &lt;2 years of age in a low TB prevalence setting in combination with the known logistical and interpretation challenges associated with TSTs support the adoption of IGRAs for this age group in certain clinical scenarios. Interpretation of IGRAs, particularly in immunocompromised patients, should involve consideration of the broader clinical context.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000003794","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T22:05:14Z","timestamp":1675375514000},"page":"189-194","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Interferon Gamma Release Assay Results and Testing Trends Among Patients Younger Than 2 Years Old at Two US Health Centers"],"prefix":"10.1097","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4843-871X","authenticated-orcid":false,"given":"Mary E.","family":"Tabatneck","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Boston Children\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"He","sequence":"additional","affiliation":[{"name":"Center for Research Information Science and Computing, Massachusetts General Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella S.","family":"Lamb","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Boston Children\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingwei","family":"Sun","sequence":"additional","affiliation":[{"name":"Center for Research Information Technology, Boston Children's Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don","family":"Goldmann","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Boston Children\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishakha","family":"Sabharwal","sequence":"additional","affiliation":[{"name":"Division of Pediatric Infectious Diseases, Boston Medical Center, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Sandora","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Boston Children\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica E.","family":"Haberer","sequence":"additional","affiliation":[{"name":"Center for Global Health, Massachusetts General Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey I.","family":"Campbell","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Boston Children\u2019s Hospital, Boston, Massachusetts"},{"name":"Division of Pediatric Infectious Diseases, Boston Medical Center, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,12,2]]},"reference":[{"key":"R1-20250614","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMra1008049","article-title":"Tuberculosis in children.","volume":"367","author":"Perez-Velez","year":"2012","journal-title":"N Engl J Med"},{"key":"R2-20250614","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1164\/rccm.200511-1809SO","article-title":"Childhood pulmonary tuberculosis: old wisdom and new challenges.","volume":"173","author":"Marais","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"R3-20250614","article-title":"Tuberculosis infection in children and adolescents: testing and treatment.","volume":"148:1-23","author":"Nolt","year":"2021","journal-title":"Pediatrics"},{"key":"R4-20250614","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.prrv.2010.09.009","article-title":"Immune-based diagnostics for TB in children: what is the evidence?","volume":"12","author":"Ling","year":"2011","journal-title":"Paediatr Respir Rev"},{"key":"R5-20250614","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1542\/pir.2018-0093","article-title":"Tuberculosis in children.","volume":"40","author":"Holmberg","year":"2019","journal-title":"Pediatr Rev"},{"key":"R7-20250614","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1086\/519266","article-title":"Interferon-gamma release assays improve the diagnosis of tuberculosis and nontuberculous mycobacterial disease in children in a country with a low incidence of tuberculosis.","volume":"45","author":"Detjen","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"RR-5","key":"R8-20250614","first-page":"1","article-title":"Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010.","volume":"59","author":"Mazurek","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"R9-20250614","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1097\/INF.0000000000002711","article-title":"Interferon-gamma release assay testing in children younger than 2 years in a US-based health system.","volume":"39","author":"Gaensbauer","year":"2020","journal-title":"Pediatr Infect Dis J"},{"key":"R10-20250614","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/cid\/ciw778","article-title":"Official American Thoracic Society\/Infectious Diseases Society of America\/centers for disease control and prevention clinical practice guidelines: diagnosis of tuberculosis in adults and children.","volume":"64","author":"Lewinsohn","year":"2017","journal-title":"Clin Infect Dis"},{"key":"R13-20250614","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/jpids\/piu119","article-title":"Interferon-gamma release assays and pediatric public health tuberculosis screening: the San Francisco program experience 2005 to 2008.","volume":"5","author":"Grinsdale","year":"2016","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R14-20250614","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jpeds.2012.04.007","article-title":"The effect of age on whole blood interferon-gamma release assay response among children investigated for latent tuberculosis infection.","volume":"161","author":"Critselis","year":"2012","journal-title":"J Pediatr"},{"key":"R15-20250614","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/INF.0b013e3181a16394","article-title":"The likelihood of an indeterminate test result from a whole-blood interferon-gamma release assay for the diagnosis of Mycobacterium tuberculosis infection in children correlates with age and immune status.","volume":"28","author":"Haustein","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"R16-20250614","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1097\/INF.0000000000000353","article-title":"Performance of interferon-\u03b3 release assay for the diagnosis of active or latent tuberculosis in children in the first 2 years of age: a multicenter study of the Italian Society of Pediatric Infectious Diseases.","volume":"33","author":"Garazzino","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"R20-20250614","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S2213-2600(17)30060-7","article-title":"Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study.","volume":"5","author":"Andrews","year":"2017","journal-title":"Lancet Respir Med"},{"key":"R21-20250614","article-title":"Interferon-\u03b3 release assay performance for tuberculosis in childhood.","volume":"141:1-11","author":"Kay","year":"2018","journal-title":"Pediatrics"},{"key":"R22-20250614","article-title":"Comparing quantiFERON-TB gold plus with other tests to diagnose mycobacterium tuberculosis infection.","volume":"57:1-9","author":"Venkatappa","year":"2019","journal-title":"J Clin Microbiol"},{"key":"R23-20250614","doi-asserted-by":"crossref","first-page":"540","DOI":"10.4269\/ajtmh.18-0674","article-title":"Evaluation of the quantiFERON-tuberculosis gold plus assay in children with tuberculosis disease or following household exposure to tuberculosis.","volume":"100","author":"Kay","year":"2019","journal-title":"Am J Trop Med Hyg"},{"key":"R24-20250614","doi-asserted-by":"crossref","first-page":"e2624","DOI":"10.1371\/journal.pone.0002624","article-title":"A three-way comparison of tuberculin skin testing, quantiFERON-TB gold and T-SPOT.TB in children.","volume":"3","author":"Connell","year":"2008","journal-title":"PLoS One"},{"key":"R25-20250614","doi-asserted-by":"crossref","first-page":"e419","DOI":"10.1542\/peds.2008-1722","article-title":"Performance of commercial blood tests for the diagnosis of latent tuberculosis infection in children and adolescents.","volume":"123","author":"Bergamini","year":"2009","journal-title":"Pediatrics"},{"key":"R26-20250614","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3389\/fped.2019.00208","article-title":"Risk factors for indeterminate interferon-gamma release assay for the diagnosis of tuberculosis in children-a systematic review and meta-analysis.","volume":"7","author":"Meier","year":"2019","journal-title":"Front Pediatr"},{"key":"R27-20250614","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1093\/cid\/ciz1138","article-title":"Tuberculosis disease In children and adolescents on therapy with antitumor necrosis factor-\u0251 agents: a collaborative, multicenter paediatric tuberculosis network European Trials Group (ptbnet) study.","volume":"71","author":"Noguera-Julian","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R28-20250614","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1136\/thoraxjnl-2016-209397","article-title":"Corticosteroids and infliximab impair the performance of interferon-\u03b3 release assays used for diagnosis of latent tuberculosis.","volume":"72","author":"Edwards","year":"2017","journal-title":"Thorax"},{"key":"R29-20250614","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.tube.2015.02.039","article-title":"The impact of anti-tuberculous antibiotics and corticosteroids on cytokine production in quantiFERON-TB gold in tube assays.","volume":"95","author":"Clifford","year":"2015","journal-title":"Tuberculosis (Edinb)"},{"key":"R30-20250614","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1513\/AnnalsATS.201811-784RL","article-title":"Calcineurin inhibitors and variation in the performance of interferon-\u03b3 release assays used to detect tuberculosis infection.","volume":"16","author":"Barton","year":"2019","journal-title":"Ann Am Thorac Soc"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000003794","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T00:04:48Z","timestamp":1749945888000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000003794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,2]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000003794","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12,2]]}}}